{"nctId":"NCT01178281","briefTitle":"Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence","startDateStruct":{"date":"2010-09-08","type":"ACTUAL"},"conditions":["Primary Myelofibrosis","MPN-associated Myelofibrosis"],"count":267,"armGroups":[{"label":"Pomalidomide 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Pomalidomide 0.5 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"China Extension: Pomalidomide 0.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Pomalidomide"]}],"interventions":[{"name":"Pomalidomide 0.5 mg","otherNames":["CC-4047; Pomalyst; Imnovid"]},{"name":"Placebo","otherNames":[]},{"name":"Pomalidomide","otherNames":["CC-4047","Pomalyst","Imnovid"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age ≥ 18 years\n* Myeloproliferative-neoplasm (MPN)-associated myelofibrosis\n* RBC-transfusion-dependence (global study):\n\n  * Average RBC-transfusion frequency ≥ 2 units/28 days over at least the 84 days immediately prior to randomization. There must be no interval \\> 42 days without ≥ 1 RBC-transfusion.\n  * Only RBC-transfusions given when the hemoglobin ≤ 90 g/L³ are scored in\n\ndetermining eligibility.\n\n* RBC-transfusions due to bleeding are not scored in determining eligibility.\n* RBC-transfusions due to chemotherapy-induced anemia are not scored in determining eligibility.\n\n  * Severe anemia (China-specific extension):\n* ≥ 2 hemoglobin concentrations ≤ 80 g/L for ≥ 84 days immediately before the day of enrollment.\n* No RBC-transfusion within 6 months prior to enrollment.\n\n  * Hemoglobin ≤ 130 g/L at randomization (global study); ≤ 80 g/L at enrollment in the China-specific extension.\n  * Bone marrow biopsy within 6 months (global study only).\n  * Inappropriate to receive blood cell or bone marrow allotransplant, erythropoietin and androgenic steroids\n  * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.\n  * Agree to follow pregnancy precautions as required by the protocol.\n  * Agree to receive counseling related to teratogenic and other risks of pomalidomide.\n  * Agree not to donate blood or semen.\n\nExclusion Criteria:\n\n* Prior blood cell or bone marrow allotransplant.\n* Use of drugs to treat MPN-associated myelofibrosis ≤ 30 days before starting study drug.\n* Treatment with erythropoietin or androgenic steroids ≤ 84 days before starting study drug.\n* Anemia due to reasons other than MPN-associated myelofibrosis.\n* Pregnant or lactating females.\n* More than 10% blasts by bone marrow examination or more than 10% blasts in blood in consecutive measurements spanning at least 8 weeks\n* Prior history of malignancies,other than the disease being studied, unless the subject has been free of the malignancy for ≥ 5 years with the following exceptions:\n\n  * Carcinoma in situ of the cervix\n  * Carcinoma in situ of the breast\n  * Incidental histologic finding of prostate cancer (T 1a or T 1b using TNM \\[tumor, nodes, metastasis\\] clinical staging system)\n* Human immunodeficiency virus (HIV) infection, active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections.\n* Prior treatment with pomalidomide.\n* Allergic reaction or rash after treatment with thalidomide or lenalidomide\n* Any of the following laboratory abnormalities:\n\n  * Neutrophils \\< 0.5x10\\^9 /L\n  * Platelets \\< 25 x 10\\^9 /L\n  * Estimated glomerular filtration rate (kidney function) \\< 30 mL/min/1.73 m²\n  * Aspartate aminotransferase (AST) and alanine transaminase (ALT) \\> 3.0 x upper limit of normal (ULN)\n  * Total bilirubin ≥ 4 x ULN;\n* Uncontrolled hyperthyroidism or hypothyroidism.\n* Deep venous thrombosis (DVT) or pulmonary embolus (PE) \\< 6 months before starting study drug\n* Clinically-important heart disease within the past 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Achieved RBC-Transfusion Independence","description":"RBC-transfusion independence was defined as the absence of RBC transfusions for any consecutive 84-day interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]}]},{"type":"PRIMARY","title":"China Extension: Number of Participants Achieving a Hemoglobin Increase of ≥ 15 g/L Compared to Baseline for ≥ 84 Consecutive Days","description":"A response in the China extension study was defined as an increase in hemoglobin ≥ 15 g/L above baseline value (in the absence of RBC transfusion) for ≥ 84 consecutive days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"The time from randomization to the death or to the latest date when participants are known to be alive. Overall survival was analyzed using Kaplan-Meier method; participants who were alive or lost to follow-up were censored at the latest date they were known to be alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":null},{"groupId":"OG001","value":"26.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of RBC-Transfusion Independence","description":"The duration of RBC-transfusion independence is the time from the date at which the first RBC-transfusion independence started to the date of another RBC-transfusion given at least 84 days after the time the transfusion independence started. The duration of the RBC-transfusion independence was analyzed using the Kaplan-Meier method. Data were censored at the end of the treatment phase for participants who had not received another RBC-transfusion after the start of transfusion independence by the end of treatment phase.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"5.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to RBC-Transfusion Independence","description":"Time to response was measured from first dose of study drug to the start of the first response. The start date of the response was defined as one day after the last date of an RBC-transfusion for participants who received a RBC-transfusion after the first dose, and as the date of the first dose of study drug for participants who received no RBC-transfusions during the 84 days after the first dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":null},{"groupId":"OG001","value":"2.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAE)","description":"A TEAE is an adverse event (AE) that starts on or after the first dose of study drug. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE),Version 4.0 and according to the following scale: Grade 1 = Mild (transient or mild discomfort; no limitation in activity; no medical intervention/therapy required); Grade 2 = Moderate (mild to moderate limitation in activity, some assistance may be needed; minimal medical intervention/therapy required); Grade 3 = Severe (marked limitation in activity, assistance usually required; medical intervention/therapy required, hospitalization possible); Grade 4 = Life-threatening (extreme limitation in activity, significant assistance or medical intervention/therapy required, hospitalization or hospice care probable); Grade 5 = Death Drug-related (related) AEs are those suspected by the Investigator as being related to administration of study drug","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"81","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Healthcare Resource Utilization","description":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in EuroQoL-5D (EQ-5D) Health Index Score","description":"EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). For the health state profile participants rate their perceived health state today on 5 dimensions: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression on a Likert-type scale from 1 to 3, where 1 = \"no problems,\" 2 = \"some problems,\" and 3 = \"extreme problems.\" The EQ-5D Health Utility Index (HUI) was generated from the five health state domain scores, and ranges from -0.594 (worst) and 1 (best) imaginable health state, with -0.594 representing an \"unconscious\" health state.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0385","spread":"0.2480"},{"groupId":"OG001","value":"-0.0298","spread":"0.2129"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0202","spread":"0.1666"},{"groupId":"OG001","value":"0.0766","spread":"0.1546"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQoL-5D (EQ-5D) Visual Analog Scale","description":"EQ-5D is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D includes 2 components: the EQ-5D health state profile (descriptive system) and the EQ-5D visual analog scale (VAS). On the VAS the participant rates his/her health state on a line from 0 (worst imaginable health) to 100 (best imaginable health).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"20.78"},{"groupId":"OG001","value":"-1.4","spread":"14.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"22.85"},{"groupId":"OG001","value":"0.3","spread":"24.25"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Total Score","description":"The FACT-An is a 47-item, cancer-specific questionnaire consisting of a core 27-item general questionnaire measuring the four general domains of QoL (physical, social/family, emotional and functional well-being), and an additional 20-item anemia questionnaire (FACT-An Anemia subscale) that measures 13 fatigue-associated items (FACT-F Fatigue subscale) and seven non-fatigue-related items. Each item is scored using a 5-point Likert rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very much). FACT-An total score is calculated by adding all the FACT-An subscales together. The total score ranges from 0-188 with higher scores representing better QOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"20.32"},{"groupId":"OG001","value":"4.3","spread":"18.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"20.49"},{"groupId":"OG001","value":"11.9","spread":"18.60"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":76,"n":167},"commonTop":["OEDEMA PERIPHERAL","FATIGUE","DIARRHOEA","PYREXIA","NAUSEA"]}}}